MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Depreciation & Amortization 2011-2026 | EXEL
Annual Depreciation & Amortization Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.1 M | 28.8 M | 25.7 M | 20.9 M | 13.6 M | 8.35 M | - | 4.92 M | 1.19 M | 1 M | 1.41 M | 2.39 M | 3.15 M | 5.51 M | 6.82 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.1 M | 1 M | 10.9 M |
Quarterly Depreciation & Amortization Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 7.34 M | - | - | - | 6.38 M | - | - | - | 6.86 M | - | 14.9 M | 9.27 M | 4.49 M | - | 11.7 M | 6.9 M | 3.23 M | - | 6.73 M | 4.38 M | 2.18 M | - | 6.09 M | 4 M | 1.96 M | - | 2.88 M | 1.18 M | 371 K | - | 842 K | 563 K | 281 K | - | 754 K | 456 K | 229 K | - | 1.06 M | 684 K | 297 K | - | 3.01 M | 1.09 M | 498 K | - | 2.38 M | 1.63 M | 842 K | - | 4.07 M | 2.64 M | 1.23 M | - | 5.04 M | 3.93 M | 1.93 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.9 M | 229 K | 3.44 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
112 K | $ 3.41 | 2.1 % | $ 300 M |  USA |
 |
Amgen
AMGN
|
5.17 B | $ 350.17 | 0.68 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 19.57 | 0.36 % | $ 915 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.64 | 1.15 % | $ 16.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | USA |
 |
Benitec Biopharma
BNTC
|
66 K | $ 11.0 | 0.18 % | $ 453 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.58 | 3.62 % | $ 185 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
311 K | $ 12.83 | 0.71 % | $ 773 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
CorMedix
CRMD
|
677 K | $ 6.29 | 0.64 % | $ 453 K | USA |
 |
CytomX Therapeutics
CTMX
|
1.2 M | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Clovis Oncology
CLVS
|
8.5 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Compugen Ltd.
CGEN
|
461 K | $ 2.12 | 1.2 % | $ 198 M | Israel |
 |
Denali Therapeutics
DNLI
|
7.8 M | $ 20.92 | 3.69 % | $ 3.44 B | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
1.4 M | $ 4.26 | 0.47 % | $ 707 M | Canada |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |